The biotech (NASDAQ: AMGN) isn't exactly known as a growth stock. Over the past few years, the company's organic revenue hasn't been increasing at a particularly impressive rate. The drugmaker has tried to improve on that front through acquisitions and developing newer products.

Though these initiatives have had a positive effect, there is still room for more progress. Here's the good news: Amgen is currently working on medicines in an exciting and fast-growing therapeutic area. If the biotech can be successful, it could be its next big growth opportunity. Let's find out more.

Business success tends to attract competitors. Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) are making small fortunes from their dominance in the weight loss market thanks to GLP-1 medicines such as Wegovy and Zepbound.

Continue reading

Source Fool.com